For Pfizer, Vaccines and Vyndaqel In The Q1 Spotlight
Earnings preview: Pfizer's newly launched rare disease drug Vyndaqel and vaccines could be impacted by COVID-19. Investors will also be eager to hear more about the timeline for closing the Upjohn transaction.
You may also be interested in...
Johnson & Johnson will move a vaccine candidate for COVID-19 into clinical testing in September and lowered 2020 financial guidance as a result of the pandemic. Pharma sales were resilient, however.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
Pfizer's COVID-19 vaccine is sure to dominate the third quarter results call, with everything from data to widescale distribution and the potential financial reward on the minds of investors and the public.